Humanized ace2-expressing transgenic mouse susceptible to sars-cov-2 virus infection and method for producing same

A method for producing a transgenic mouse, comprising:

• (a) introducing into a mouse embryo donor DNAs together with the components of gene-editing technology for each exon, wherein
• (i) the donor DNA for exon 1 comprises a nucleotide sequence encoding amino acids 24-34 including the four human amino acids 24Q, 30D, 31 K, and 34H, so that the four mouse amino acids N24, N30, N31, and Q34 are substituted with the human amino acids 24Q, 30D, 31 K, and 34H;
• (ii) the donor DNA for exon 2 comprises a nucleotide sequence encoding amino acids 79-84 including the four human amino acids 79L, 82M, 83Y, and 84P, so that the four mouse amino acids T79, S82, F83, and S84 are substituted with the human amino acids 79L, 82M, 83Y, and 84P;
• and
• (iii) the donor DNA for exon 8 comprises a nucleotide sequence encoding the human amino acid 353K, so that the mouse amino acid H353 is substituted with the human amino acid 353K,
• wherein the numbers indicate the amino acid positions in the mouse ACE2 amino acid sequence of Sequence ID No. 1 or the humanized ACE2 amino acid sequence of Sequence ID No. 3, the amino acid to the left of the number denotes the wild-type mouse amino acid, and the amino acid to the right of the number denotes the humanized mouse amino acid;
• (b) implanting the mouse embryo into a surrogate uterus to obtain individuals;
• and
• (c) selecting individuals (founders) in which the donor DNA has been inserted.